Licensing deals for Philogen with Pfizer and GlycoVaxyn with Janssen

7 January 2013

Privately held Italian biopharma firm Philogen SpA (Siena, Italy) has granted global drugs behemoth Pfizer (NYSE:PFE) a worldwide license to Philogen's Dekavil, an immunocytokine consisting of a vascular targeting antibody fused to the anti-inflammatory cytokine IL-10.

Currently in Phase I clinical testing, Dekavil is designed as an "armed antibody" which selectively targets inflammatory disease sites in the body instead of suppressing the immune system, Philogen explained.

The product is in Phase I testing for rheumatoid arthritis in combination with methotrexate. Pfizer, which also plans to develop Dekavil for inflammatory bowel disease (IBD), has exclusive rights to market any products developed out of the deal. Philogen will receive an undisclosed upfront payment and is eligible for milestones, plus royalties.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK